A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Epetraborole Tablets and the Impact of Alcohol Dehydrogenase (ADH) Genotype on the PK of Epetraborole and Metabolite M3 in Healthy Japanese Adult Subjects
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Epetraborole (Primary)
- Indications Melioidosis; Nontuberculous mycobacterium infections
- Focus Pharmacokinetics
Most Recent Events
- 11 Oct 2023 According to an AN2 Therapeutics media release, company will be presented data from this trial at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.
- 06 Oct 2022 Results published in the AN2 Therapeutics Media Release
- 06 Oct 2022 Status changed from active, no longer recruiting to completed as per AN2 Therapeutics media release